CHF Solutions (NASDAQ:CHFS) Issues Earnings Results, Misses Estimates By $0.47 EPS

CHF Solutions (NASDAQ:CHFS) posted its quarterly earnings data on Tuesday. The company reported ($1.93) EPS for the quarter, missing analysts’ consensus estimates of ($1.46) by ($0.47), Morningstar.com reports. CHF Solutions had a negative return on equity of 188.60% and a negative net margin of 336.26%. The firm had revenue of $1.68 million during the quarter.

CHF Solutions stock traded up $0.07 during midday trading on Wednesday, reaching $2.49. The stock had a trading volume of 88,854 shares, compared to its average volume of 133,521. The firm has a fifty day moving average of $2.88. CHF Solutions has a twelve month low of $2.15 and a twelve month high of $20.02. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.12 and a current ratio of 5.86. The firm has a market cap of $5.68 million, a price-to-earnings ratio of -0.06 and a beta of 2.37.

A hedge fund recently bought a new stake in CHF Solutions stock. Perkins Capital Management Inc. purchased a new position in shares of CHF Solutions Inc (NASDAQ:CHFS) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 114,285 shares of the company’s stock, valued at approximately $470,000. Perkins Capital Management Inc. owned about 17.32% of CHF Solutions at the end of the most recent reporting period. 10.17% of the stock is owned by institutional investors.

A number of research firms recently commented on CHFS. Zacks Investment Research lowered shares of CHF Solutions from a “hold” rating to a “sell” rating in a research note on Monday, July 8th. ValuEngine raised shares of CHF Solutions from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.

About CHF Solutions

CHF Solutions, Inc, a medical device company, focuses on the provision of solutions for patients suffering from fluid overload. The company's commercial product is the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Featured Story: What are Bollinger Bands?

Earnings History for CHF Solutions (NASDAQ:CHFS)

Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.